GSK in talks to buy Nuvalent for more than $9 billion

GSK is in talks to acquire cancer drugmaker Nuvalent for more than $9 billion, the Financial Times reported Monday, citing people familiar with the matter.

The potential acquisition would mark one of the largest biotech buyouts of the year, giving the UK pharmaceutical group access to Nuvalent's pipeline of precision oncology therapies. Nuvalent, a Massachusetts-based biotech, focuses on developing small-molecule drugs targeting genetic drivers of cancer, including its lead program for ROS1-positive non-small cell lung cancer.

Reuters could not immediately verify the report. Neither GSK nor Nuvalent responded to requests for comment outside regular business hours.

A deal at the reported price would represent a significant premium to Nuvalent's market value before the news broke, though the exact terms of any potential transaction remain under negotiation. The acquisition would bolster GSK's oncology portfolio as the company seeks to strengthen its drug pipeline ahead of patent expirations on key products.

The talks come amid a broader wave of pharmaceutical M&A, with large drugmakers seeking to replenish pipelines through acquisitions of smaller biotech firms. Any deal would likely face regulatory review in both the US and UK, given the size of the transaction and its implications for cancer drug development.

This article is for informational purposes only and does not constitute investment advice.